Navigation Links
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Date:1/12/2009

Research and Development for Sunesis. "Our combination study has shown complete remissions and a manageable safety profile. Both studies are continuing to enroll well, and, pending final clinical data, allow us to explore potential registration strategies in either newly diagnosed or first relapse AML populations."

Phase 2 Trial of Voreloxin in Platinum-Resistant Ovarian Cancer

Enrollment is complete for the Phase 2 study of voreloxin in platinum-resistant ovarian cancer. Three schedules of voreloxin have been studied, 48 mg/m2 given every three weeks (N=65), and 60 mg/m2 (N=37) and 75 mg/m2 (N=35) given every four weeks. As reported at the 12th Biennial Meeting International Gynecologic Cancer Society, two complete responses and five partial responses were observed at 48 mg/m2. Thirty patients (46%) achieved disease control, defined as stable disease for 90 days or more or a complete or partial response. Median progression free survival is 82 days. All patients at this dose level are now off-study. Data are maturing for both the 60 and 75 mg/m2 cohorts. One complete response and three partial responses of thirty-four patients for whom data are available are reported thus far at 60 mg/m2; nine patients remain on study. Early response data on ten patients at 75 mg/m2 show one partial response to date and five patients with stable disease; twenty patients remain on study. Voreloxin was generally well-tolerated at 48 and 60 mg/m2, with an incidence of febrile neutropenia of below 10%. An increase in febrile neutropenia is observed at 75 mg/m2, although the incidence remains below 20%.

About Voreloxin

Voreloxin is a novel naphthyridine analog, structurally related to quinolones, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-sele
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis to Present at Upcoming Conferences
2. Sunesis to Present at Upcoming Conferences
3. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
4. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
6. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
7. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
8. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
9. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
10. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
11. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... 9, 2010 Federico Capasso, Robert L. Wallace Professor ... in Electrical Engineering at the Harvard School of Engineering ... Berthold Leibinger Zukunftspreis (the future prize), an international award ... laser light. The prize, consisting of 30,000, will ...
... future molecular devices, new display technologies, and "artificial muscles" ... a primary role. Rotaxanes, one ... that consist of a dumbell-shaped molecule whose rod section ... molecular "machines," with the ring moving along the rod ...
... July 6 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd.,(Nasdaq: DHRM ), ... and homecare medical products in China , announced,today that it has ... for RMB11 million (about $1.58 million ). , ... The patented ...
Cached Biology Technology:Laser pioneer Federico Capasso awarded Berthold Leibinger Zukunftspreis 2Study measures single-molecule machines in action 2Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract 2Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract 3Dehaier Medical Systems Signs $1.6 Million Oxygen-Chip Sales Contract 4
(Date:4/16/2014)... childhood, associated with structural changes in the hippocampus ... New research from UC Davis is exploring how ... Eventually, that could give insights into disorders that ... adolescence and affect memory, such as schizophrenia and ... the brain, the hippocampus plays a key role ...
(Date:4/16/2014)... Dr. Panagiotis Papatheodorou from the Institute of Experimental and ... have discovered the receptor responsible for smuggling the toxin ... cell. The TpeL toxin, which is formed by ... and food poisoning. It is very similar to the ... Clostridium . The toxins bind to surface molecules ...
(Date:4/15/2014)... neurobiologists have found that genetically modified neural stem cells ... mice with the symptoms and pathology of Alzheimer,s disease. ... Stem Cells Research and Therapy , and the approach ... models. , Alzheimer,s disease, one of the most ... the protein amyloid-beta in the brain in the form ...
Breaking Biology News(10 mins):How kids' brain structures grow as memory develops 2Gate for bacterial toxins found 2UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2
... adhesion are very important in fundamental research on ... have been extensively investigated during the last decade. ... have conventionally been used to block cell adhesion. ... reported that the purple membrane (PM) containing a ...
... have been awarded $3.1 million by the National Institute ... Health, to study and develop several new compounds that ... the unwanted side effects common with opiate drugs, such ... an associate professor in the Department of Molecular Therapeutics ...
... rapidly, so quickly identifying them can be crucial to ... can take hours and days. But not for much ... science and electrical engineering at the University of Tennessee, ... and Fisheries at the UT Institute of Agriculture Center ...
Cached Biology News:New function of a bacterial photoresponsive protein: Resisting adhesion of mammalian cells 2Scripps Florida scientists awarded $3 million to develop new, more effective pain treatments 2University of Tennessee researchers invent device to rapidly detect infectious disease 2
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
Rabbit polyclonal to ZA20D3 ( Abpromise for all tested applications). entrezGeneID: 54469 SwissProtID: Q6FIF0...
... Rabbit polyclonal to Oct6 ( Abpromise ... Synthetic peptide conjugated to KLH derived from ... (Note: the amino acid sequence is proprietary) ... .) Entrez Gene ID: ...
ATP-binding cassette sub-family D member 4 (Peroxisomal membrane protein 69) (PMP69) (Peroxisomal membrane protein 1-like) (PXMP1-L) (P70R). [Source:Uniprot/SWISSPROT;Acc:O14678] Antigen: Recombi...
Biology Products: